Shanghai Junshi Biosciences completes $450 million IPO on The Stock Exchange of Hong Kong Limited
Client(s) Shanghai Junshi Biosciences Co., Ltd.
Jones Day acted as Hong Kong and U.S. counsel for Shanghai Junshi Biosciences Co., Ltd. in connection with its over $450 million initial public offering on The Stock Exchange of Hong Kong Limited and concurrent Rule 144A and Regulation S offerings. The Company is the first H shares company listing under the newly-implemented HKSE Listing Rules allowing for pre-revenue biotech companies to be listed on the Main Board of the HKSE. The Company is also the first company with its shares listed on both the HKSE and the P.R.C. National Equities Exchange and Quotations.
Shanghai Junshi Biosciences Co., Ltd. is an innovation-driven biopharmaceutical company dedicated to the discovery and development of innovative drugs and their clinical research and commercialization on a global scale. The company is the first P.R.C. company to file Investigational New Drug (“IND”) application and New Drug Application with the National Medical Products Administration of China (“NMPA”) for anti-PD-1 monoclonal antibody (JS001 or toripalimab) and the first P.R.C. company to receive IND approvals from the NMPA for anti-PCSK9 monoclonal antibody and anti-BLyS monoclonal antibody.
The Company has developed a product pipeline comprising 13 biologic drug candidates, including seven immuno-oncology drug candidates, two drug candidates for metabolic diseases, three targeting inflammation or autoimmune diseases, and one to treat neurologic diseases. The NMPA has conditionally granted approval for the abovementioned JS001.
